FDA Expert Panel Recommends Approval of Pargluva

Drug Industry Daily
KEYWORDS FDA / Rx
A A

An FDA advisory panel has recommended approving the experimental diabetes drug Pargluva, which was co-developed by Bristol-Myers Squibb (BMS) and Merck, despite concerns over the product’s cardiovascular risks.

To View This Article:

Login

Subscribe To Drug Industry Daily